BPC-157 in Australia — research guide, purity and pricing

BPC-157 is a synthetic fragment derived from a sequence identified in gastric juice. It is short, stable in aqueous solution relative to many peptides, and inexpensive to synthesise — which is why it appears so often in preclinical work.

It is not a registered therapeutic good in Australia and is supplied as a laboratory reference material only.

The literature is largely preclinical — cell culture and animal models examining tissue-repair signalling, angiogenesis-related pathways and gastrointestinal models.

Human clinical evidence is limited. We make no claims about effects in humans; read the primary sources linked below and assess them yourself.

BPC-157 is generally reconstituted with bacteriostatic water and refrigerated. Aliquoting into single-use volumes avoids repeated freeze-thaw cycles that degrade peptide integrity.

Label every aliquot with the lot number so results stay traceable to the batch CoA.

Lyophilised (freeze-dried) peptides are shipped cold-chain packed and are typically stored at -20°C for long-term storage, or 2-8°C for short periods before reconstitution.

Once reconstituted with bacteriostatic water, vials are generally refrigerated at 2-8°C and protected from light and repeated freeze-thaw cycles.

Every Aussie Peptides vial carries a lot number that maps to a batch Certificate of Analysis, so purity and identity can be recorded alongside your experimental data.

Materials on this site are supplied strictly for in-vitro laboratory research. They are not therapeutic goods, are not approved by the TGA for human use, and are not supplied for human or veterinary consumption.

Purchasers must be 18 or over and are responsible for handling, storing and disposing of research materials in line with their institution's requirements and applicable Australian law.

Nothing on this page is medical advice, a dosing protocol, or a claim of therapeutic benefit. It summarises what the published research literature investigates.